{"id":"NCT01930188","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes","officialTitle":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-02","primaryCompletion":"2015-10-12","completion":"2015-10-12","firstPosted":"2013-08-28","resultsPosted":"2019-01-07","lastUpdate":"2019-06-13"},"enrollment":1231,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"semaglutide","otherNames":[]},{"type":"DRUG","name":"sitagliptin","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Semaglutide 0.5 mg + sitagliptin placebo","type":"EXPERIMENTAL"},{"label":"Semaglutide 1.0 mg + sitagliptin placebo","type":"EXPERIMENTAL"},{"label":"Sitagliptin 100 mg + semaglutide placebo 1.0 mg","type":"ACTIVE_COMPARATOR"},{"label":"Sitagliptin 100 mg + semaglutide placebo 0.5 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD (thiazolidinedione) in subjects with type 2 diabetes.","primaryOutcome":{"measure":"Change in HbA1c (Glycosylated Haemoglobin) From Baseline","timeFrame":"Week 0, week 56","effectByArm":[{"arm":"Semaglutide 0.5 mg + Sitagliptin Placebo","deltaMin":-1.32,"sd":0.05},{"arm":"Semaglutide 1.0 mg + Sitagliptin Placebo","deltaMin":-1.61,"sd":0.05},{"arm":"Sitagliptin + Semaglutide Placebo","deltaMin":-0.55,"sd":0.05}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":141,"countries":["Argentina","Bulgaria","Czechia","Hong Kong","Hungary","India","Japan","Mexico","Norway","Portugal","Romania","Russia","South Africa","Spain","Sweden","Thailand","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["30938762","30865526","28385659","29748996","29766634","29764222","29862621","29907893","30615985","37178435","32998732","32827435","32193837","31903692","31769496","31215727"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":409},"commonTop":["Nausea","Diarrhoea","Nasopharyngitis","Lipase increased","Vomiting"]}}